Janux Therapeutics: Buying For The Promising Pipeline, Holding For The Buyout
Janux Therapeutics' lead drug, JANX007, shows promising prostate cancer results with no serious side effects. Find out why ...
Novartis price target raised to CHF 115 from CHF 110 at Deutsche Bank
Deutsche Bank analyst Emmanuel Papadakis raised the firm’s price target on Novartis (NVS) to CHF 115 from CHF 110 and keeps a Buy rating on the ...
Oncology Nurse Advisor2d
177Lu PSMA Effective After 223Ra in Real-World Patients With mCRPC
The radiopharmaceutical lutetium 177 can be used after radium 223 to treat metastatic castration-resistant prostate cancer.
Deutsche Bank Remains a Buy on Novartis AG (NOVN)
Deutsche Bank analyst Emmanuel Papadakis maintained a Buy rating on Novartis AG (NOVN – Research Report) today and set a price target of ...
MOASC Honors Young Investigator, Advancing Oncology Research
The Medical Oncology Association of Southern California (MOASC) presented the highly anticipated 2025 Cary Presant, MD Young ...
The Financial Express3d
Bayer Pharma to expand cardiology, women’s health portfolios with new drugs this year
The company is expanding its cardiology portfolio with a new treatment for transthyretin amyloid cardiomyopathy in Europe.
Oncology Nursing News3d
Oncology Drugs Approved by the FDA in March 2025
The FDA approved several therapies in oncology in the month of March 2025. These drugs included treatments for ...
Targeted Oncology3d
Novel ADC Shows Promise of Targeting CD46 in mCRPC
The antibody-drug conjugate FOR46 showed the strong potential of using CD46 as a new therapeutic target in metastatic ...
OncoHelix and AstraZeneca Partner to Provide Access to Liquid Biopsy Testing for Men with Prostate Cancer
OncoHelix, a leader in precision diagnostics, is proud to announce its partnership with AstraZeneca Canada to deliver cutting-edge liquid biopsy testing for men with metastatic castration-resistant ...
PMLive4d
Novartis’ Pluvicto granted FDA approval for expanded prostate cancer use
Novartis’ radioligand therapy Pluvicto (lutetium Lu 177 vipivotide tetraxetan) has been approved by the US Food and Drug ...
Renal & Urology News4d
FDA Expands Approval of Pluvicto in PSMA-Positive Metastatic CRPC
The FDA expanded the approval of Pluvicto (lutetium Lu 177 vipivotide tetraxetan) to include patients with PSMA-positive mCRPC who have been treated with ARPI therapy and are considered appropriate to ...
The Pharma Letter5d
Novartis’ Pluvicto gets FDA green light for mCRPC
Novartis (NOVN: VX) announced late Friday that the US Food and Drug Administration (FDA) approved Pluvicto (lutetium Lu 177 ...